Comments: Cetaphil restaged in 2024, revamping its look and feel with a bold, refreshed visual transition—which for a 77-year-old brand, is a pretty big deal! The rebrand aims to reach new consumers with education and sensitive skin solutions through a modern approach. Rooted in research from the Galderma Global Sensitive Skincare Faculty (GSSF), which uncovered that sensitive skin affects 70% of consumers, the brand is more passionate than ever about reaching new consumers.

The new playbook introduces updated product silhouettes, modern typography and a refined color palette, all while staying rooted in its trusted, science-backed formulations. To launch the rebrand, Cetaphil debuted “For Everyone’s Sensitive Skin,” a new marketing campaign that celebrates diverse stories.

In other news, Galderma brand Differin is redefining acne care for Gen Z and young adults, turning product education into an engagement driver with a “category-first activation” within the Roblox gaming world. Differin’s new Level Up Lobby not only gamifies acne education, it demystifies the skin condition by blending information with gameplay making acne-care approachable and actionable.

Galderma established its new US headquarters in Miami, FL. The Miami location positions Galderma at the heart of a thriving market for dermatological skincare, officials said. Located in the Brickell neighborhood, the company expects to have approximately 150 employees there by 2028. In addition to its new headquarters in Miami, Galderma will maintain a strong presence across several US locations. Boston will remain the hub for the company’s US Therapeutic Dermatology business and US R&D organization. Carlsbad, CA will continue as a hub for Alastin, the company’s physician-dispensed skincare brand. The Dallas, TX, office remains one of Galderma’s key US sites while the North America distribution center remains in Fort Worth, TX.

Galderma has 6,500 employees—55% of them, women.

Key Personnel: Flemming Ørnskov, MD, MPH, chief executive officer; Thomas Dittrich, chief financial officer; Allison Pinkham, chief human resources officer; Adrian Murphy, global head of operations

Major Products: Skincare (Alastin, Cetaphil, Differin); prescription dermatology treatments; injectable aesthetics

New Products: Cetaphil—Vitamin C Serum, Ceramide Serum, Healthy Renew

Comments: Galderma Group AG is a pure-play dermatology company, and as of March 22, 2024, is publicly listed on the SIX Swiss Exchange. It represented the largest IPO placement in Switzerland since 2017, according to the Exchange.

Galderma’s  dermatological skincare unit—home to Cetaphil, Differin and Alastin—recorded net sales of $351 million in Q1 2024, with year-on-year growth of 8.4% on a constant currency basis. The growth overall was mainly driven by volume and favorable product mix, according to officials. Cetaphil in international markets and Alastin both grew double-digits more than offsetting market softness in the US skincare market and lower US consumption of Cetaphil, according to the company.

“We started the year strong, continuing on Galderma’s growth trajectory and celebrating our first days of trading on the SIX Swiss Exchange. This is a testament to our proven integrated dermatology strategy and the focus of our employees globally, each committed to serving our healthcare professionals, consumers and patients worldwide. With attractive growth across our product categories and geographies, we are confident in our financial outlook for the year,” said CEO Flemming Ørnskov, MD, MPH.

In 2023, Cetaphil reached the $1 billion net sales mark for the first time in its history. According to Galderma, nine out of 10 US dermatologists recommend Cetaphil to their patients.

The mass market skincare brand has been taking bold steps to grow awareness with more consumers. For example, Cetaphil brand activations reached more than 5 billion impressions globally through campaigns for two events in the first quarter of 2024—#FaceOfCetaphil at New York Fashion Week and the #GameTimeGlow for the Super Bowl—along with locally tailored promotional activities.

More recently, Cetaphil rolled out a new campaign around Father’s Day designed to reach men.

Sales: $1.1 billion

Comments: Galderma is a privately-held company and the world’s largest independent dermatology company, with annual sales of $3.7 billion. It is present in approximately 100 countries. Galderma’s portfolio includes brands and services across aesthetics, consumer care and prescription medicine.

The company recently raised about $1 billion through a private placement of shares after plans for a stock market listing were delayed. The newly-issued shares are being divvied up between shareholders and management and undisclosed external investors per officials. Proceeds will be used to buttress its balance sheet and accelerate growth.

Galderma had a strong presence at the 25th World Congress of Dermatology (WCD) in Singapore last month. It presented almost 60 abstracts and convened separate symposium from Galderma’s Sensitive Skincare Faculty in collaboration with George Washington University.

Galderma also hosted an acne symposium at WCD featuring new phase IV study data investigating the efficacy and safety of trifarotene cream on acne and the risk of formation of acne scars.

ReSurface Skin Polish delivers the power of dual-action exfoliation through volcanic minerals and glycolic acid in a non-irritating, hydrating formula. The product is clinically proven to help improve tactile roughness and skin dullness in a week.

Sales: $1.3 billion

Galderma is a privately-held company and the world’s largest independent dermatology company, present in approximately 100 countries. Its portfolio includes sophisticated brands and services across aesthetics, consumer care and prescription medicine.

In February 2022, Galderma and Taro Pharmaceutical Industries Ltd. signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company. The agreement includes Alchemee’s business and assets around the world, including the Proactiv brand.

Also making news for Galderma in 2022 is its leading mass market brand Cetaphil. The sensitive skin care leader has revamped its skin care products with “new and improved” formulas featuring a dermatologist-backed blend of niacinamide (vitamin B3), panthenol (vitamin B5) and hydrating glycerin to improve skin’s overall resilience. The brand debuted its Sensitive Skin Awareness Month this past March, a digitally focused marketing campaign that arms consumers with science-backed guidance on how to identify, care for, and treat sensitive skin of all kinds.

Cetaphil revamped its skin care products with “new and improved” formulas featuring a dermatologist-backed blend of niacinamide, panthenol and hydrating glycerin to improve skin’s overall resilience.